Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents

Bibliographic Details
Title: Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents
Authors: Yubin Hai, Tingting Lin, Guangyi Wang, Xiaodong Sun, Lan Wang, Yuying Hai, Saisai Chen, Xiaoju Shi
Source: Frontiers in Oncology, Vol 14 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: hepatocellular carcinoma, tumor thrombus, hepatectomy, targeted and immunotherapeutic drugs, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality. Tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) significantly worsens prognosis. We present four cases of male patients (average age 57) with HCC and TT extending into the IVC/RA, treated at our center. All underwent hepatectomy and TT resection, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) administered post-operatively. Case 1 involved a 59-year-old male who had a right hepatectomy and TT resection in the IVC, followed by targeted therapy and immunotherapy, and is currently alive 74 months post-treatment. Case 2, a 48-year-old male, had a right hepatic lobectomy and TT resection in the IVC/RA, followed by liver transplantation 54 months postoperatively, with no recurrence. Case 3, a 66-year-old male, underwent a left hepatectomy and TT resection in the IVC, remaining disease-free 27 months postoperatively. Case 4, a 55-year-old male, received 15 cycles of combined targeted and immune therapy, followed by left hepatectomy and TT resection in the IVC/RA, with no recurrence 22 months postoperatively. Surgical resection combined with targeted and immunotherapy may enhance survival in advanced HCC patients with TT in the IVC/RA. Further studies are required to corroborate these findings.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1470374/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2024.1470374
Access URL: https://doaj.org/article/8c223d56e1a0403fa3d546cb45ed5bf7
Accession Number: edsdoj.8c223d56e1a0403fa3d546cb45ed5bf7
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2024.1470374
Published in:Frontiers in Oncology
Language:English